Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases in the United States.
Excellent balance sheet and fair value.
Share Price & News
How has Cidara Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CDTX's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: CDTX exceeded the US Biotechs industry which returned 27.6% over the past year.
Return vs Market: CDTX exceeded the US Market which returned 9.5% over the past year.
Price Volatility Vs. Market
How volatile is Cidara Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall StDo Institutions Own Shares In Cidara Therapeutics, Inc. (NASDAQ:CDTX)?
4 months ago | Simply Wall StHave Insiders Been Buying Cidara Therapeutics, Inc. (NASDAQ:CDTX) Shares This Year?
10 months ago | Simply Wall StDid You Manage To Avoid Cidara Therapeutics's (NASDAQ:CDTX) Devastating 86% Share Price Drop?
Is Cidara Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CDTX ($3.62) is trading below our estimate of fair value ($25.9)
Significantly Below Fair Value: CDTX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CDTX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: CDTX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CDTX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CDTX is good value based on its PB Ratio (2.7x) compared to the US Biotechs industry average (3.6x).
How is Cidara Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CDTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CDTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CDTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CDTX's revenue (60.3% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: CDTX's revenue (60.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CDTX's Return on Equity is forecast to be high in 3 years time
How has Cidara Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CDTX is currently unprofitable.
Growing Profit Margin: CDTX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CDTX is unprofitable, and losses have increased over the past 5 years at a rate of -13.2% per year.
Accelerating Growth: Unable to compare CDTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CDTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: CDTX has a negative Return on Equity (-77.82%), as it is currently unprofitable.
How is Cidara Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: CDTX's short term assets ($80.6M) exceed its short term liabilities ($29.6M).
Long Term Liabilities: CDTX's short term assets ($80.6M) exceed its long term liabilities ($716.0K).
Debt to Equity History and Analysis
Debt Level: CDTX's debt to equity ratio (18.5%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if CDTX's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CDTX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CDTX has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 16.4% each year.
What is Cidara Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CDTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CDTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CDTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CDTX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CDTX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jeff Stein (64yo)
Dr. Jeffrey L. Stein, also known as Jeff, Ph.D., has been the Chief Executive Officer, President and Executive Director of Cidara Therapeutics, Inc. since January 2014. Dr. Stein was Principal Financial Of ...
CEO Compensation Analysis
Compensation vs Market: Jeff's total compensation ($USD1.45M) is above average for companies of similar size in the US market ($USD593.13K).
Compensation vs Earnings: Jeff's compensation has increased whilst the company is unprofitable.
|Chief Business Officer||3.83yrs||US$796.48k||0.12% $182.1k|
|Chief Medical Officer||3.58yrs||US$774.09k||0.18% $265.5k|
|Founder and Chief Strategy Officer||3.83yrs||US$613.24k||no data|
|Chief Financial Officer||1.42yrs||no data||0.15% $224.0k|
|COO & Chief Commercial Officer||2.33yrs||US$662.42k||0.11% $161.2k|
|Principal Accounting Officer||1.75yrs||no data||no data|
|General Counsel & Secretary||1.58yrs||no data||0.0024% $3.5k|
|Chief Development Officer||5.83yrs||US$335.42k||no data|
|Senior Vice President of Research||5.17yrs||no data||no data|
Experienced Management: CDTX's management team is considered experienced (3.7 years average tenure).
|Independent Chairman of the Board||0.83yr||US$84.16k||0.015% $21.7k|
|Independent Director||5.17yrs||US$64.45k||0.0098% $14.5k|
|Independent Director||6yrs||US$69.45k||no data|
|Independent Director||1.58yrs||US$55.70k||no data|
|Independent Director||2.17yrs||US$64.45k||no data|
Experienced Board: CDTX's board of directors are considered experienced (3.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 52.9%.
Cidara Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Cidara Therapeutics, Inc.
- Ticker: CDTX
- Exchange: NasdaqGM
- Founded: 2012
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$147.502m
- Shares outstanding: 40.75m
- Website: https://www.cidara.com
Number of Employees
- Cidara Therapeutics, Inc.
- 6310 Nancy Ridge Drive
- Suite 101
- San Diego
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CDTX||NasdaqGM (Nasdaq Global Market)||Yes||Common Shares||US||USD||Apr 2015|
|20D||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Apr 2015|
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases in the United States. Its lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. The company, through its Cloudbreak platform, focuses on the treatment of infectious diseases that include viral and bacterial infections. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/31 05:49|
|End of Day Share Price||2020/05/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.